NY-SPRINKLR
8.12.2020 10:02:06 CET | Business Wire | Press release
Sprinklr , the Customer Experience Management (CXM) platform for modern enterprises, today announced that Nordea , the largest financial services group in Northern Europe, is expanding its use of Sprinklr to deliver digital, personalized banking experiences.
After replacing legacy systems with Sprinklr three years ago because it needed a scalable platform, Nordea has grown its partnership with Sprinklr and is now leveraging four Sprinklr products to create a collaborative, company-wide digital banking strategy.
The Challenge: Growing Company, Changing Customer Behavior & Siloed Reporting
Corporate growth combined with a substantial increase in digital engagement , undefined marketing goals, and disconnected teams created an opportunity for Nordea to develop a strategic digital vision with strong execution capabilities.
The Solution: A Company-Wide Digital Banking Strategy on Sprinklr
Nordea’s marketing team, customer service department, and agencies collaborate in one Sprinklr platform.
With Sprinklr Modern Advertising , Nordea has a single source of truth for agencies and in-house teams to view real-time ad reporting data.
With benchmarking in Sprinklr Modern Research , Nordea can understand where they stand compared to competitors across countries, and can track trending topics and themes in Swedish, Norwegian, Finnish, Danish, and English. Nordea also works with Sprinklr to improve sentiment tracking for Nordic languages.
With Sprinklr Modern Care , the company has dramatically improved the efficiency of their support team. Nordea can use Sprinklr to easily understand if customers are asking questions about specific services – such as a business loan – and quickly connect them to the relevant care agent.
With Sprinklr Modern Engagement , Nordea has one content calendar to collaborate, publish, and plan marketing and engagement campaigns across Twitter, Facebook, Instagram, LinkedIn, and YouTube and answer inquiries on Google My Business and Trustpilot.
Comments on the News:
“Nordea is committed to being the bank of the future that our customers need,” said Elizabeth Fjellerup, Group CMO at Nordea. “Sprinklr provides us with a single platform to enhance every customer experience while empowering our teams to work together with the insights they need to make smart decisions.”
“Nordea is driving digital transformation forward within the financial services industry,” said Pavitar Singh, Chief Technology Officer, Sprinklr. “By implementing a single, companywide Sprinklr platform, Nordea has a clear understanding of its marketing and customer service performance along with deep customer insight. We’re proud to support Nordea’s commitment to delivering an easy digital banking experience.”
Additional Resources:
- Request a Sprinklr demo .
- Read Sprinklr Customer Stories .
About Sprinklr
Sprinklr (@Sprinklr ) is the world’s leading Customer Experience Management (CXM) platform. We help organizations reach, engage and listen to customers across 26 social channels, 11 messaging channels, and hundreds of millions of forums, blogs, and review sites. Sprinklr is a global company with 1,900 employees helping the world’s most valuable enterprises make their customers happier.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005160/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
